Novartis

BioNTech signed a share purchase agreement with Novartis to acquire its GMP certified manufacturing facility in Marburg, Germany, to expand COVID-19 vaccine production capacity by up to 750 million doses per year.

Biofourmis acquired Swiss wearable biosensor company Biovotion for cash and equity, including its Everion device and patents. Separately, Biofourmis partnered with Novartis for commercial rollout of a heart failure management platform using AI and the Everion sensor, starting in Asia.

SomaLogic has entered into a new ten-year agreement with Novartis to expand the use of its SomaScan proteomic platform across Novartis's drug development, including analysis of at least 250,000 clinical samples.

Recordati signed an agreement with Novartis to acquire worldwide rights to Signifor and Osilodrostat for $390 million, with Novartis supplying products during a transitional period.

AveXis, a Novartis company, announced an additional $60 million investment and 200 new jobs at its gene therapy manufacturing site in Durham, North Carolina, bringing total investment to $115 million and planned employment to 400. The facility is expected to be completed in the second half of 2020.

Novartis AG completed its acquisition of Endocyte Inc. for $24 per share in cash, totaling approximately $2 billion. The deal was originally announced on October 17, 2018.

Novartis announced plans to construct a new cell and gene therapy production facility in Stein, Switzerland, with phased investments of approximately CHF 90 million ($92 million). The plant will support CAR-T drug Kymriah and create up to 450 jobs.

AveXis, a Novartis company, is investing $55 million to build a new manufacturing facility in Durham, North Carolina, creating 200 jobs. The facility will produce gene therapy AVXS-101 for spinal muscular atrophy.